Published in Nucl Med Biol on January 01, 2005
Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev (2010) 2.70
Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS One (2010) 1.86
Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med (2008) 1.63
Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry. Bioconjug Chem (2011) 1.45
Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regions. Br J Radiol (2010) 1.36
Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging (2008) 1.26
Detection of Cancer Metastases with a Dual-labeled Near-Infrared/Positron Emission Tomography Imaging Agent. Transl Oncol (2010) 1.26
Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging (2007) 1.23
Near infrared fluorescent optical imaging for nodal staging. J Biomed Opt (2008) 1.21
Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. MAbs (2010) 1.09
A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression. J Nucl Med (2009) 1.09
Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy. Radiology (2008) 1.08
Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging (2006) 1.06
Comparison of bifunctional chelates for (64)Cu antibody imaging. Eur J Nucl Med Mol Imaging (2010) 0.98
Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting. Bioconjug Chem (2011) 0.88
A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT. EJNMMI Res (2011) 0.88
An EGFR targeted PET imaging probe for the detection of colonic adenocarcinomas in the setting of colitis. Theranostics (2014) 0.85
Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res (2010) 0.84
[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging (2005) 0.84
Assessment of free dye in solutions of dual-labeled antibody conjugates for in vivo molecular imaging. Mol Imaging Biol (2011) 0.84
In vivo targeting of HER2-positive tumor using 2-helix affibody molecules. Amino Acids (2011) 0.81
Protein-based tumor molecular imaging probes. Amino Acids (2010) 0.81
Effect of microencapsulation shear stress on the structural integrity and biological activity of a model monoclonal antibody, trastuzumab. Pharmaceutics (2011) 0.80
Production and Quality Control of [(67)Ga]-DOTA-trastuzumab for Radioimmunoscintigraphy. Iran J Pharm Res (2013) 0.79
Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancer. Am J Nucl Med Mol Imaging (2014) 0.78
Antibody-based imaging of HER-2: moving into the clinic. Curr Mol Med (2013) 0.76
Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer. Eur J Nucl Med Mol Imaging (2017) 0.75
(99m)Tc-radiolabeled GE11-modified peptide for ovarian tumor targeting. Daru (2017) 0.75
Preparation and characterization of anti-tissue factor single-chain variable fragment antibody for cancer diagnosis. Cancer Sci (2014) 0.75
Feasibility evaluation of radioimmunoguided surgery of breast cancer. Int J Mol Imaging (2012) 0.75
Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma. Arch Dermatol (2008) 2.24
AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther (2004) 2.08
Cellular dosimetry of (111)In using monte carlo N-particle computer code: comparison with analytic methods and correlation with in vitro cytotoxicity. J Nucl Med (2010) 2.07
Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage. Breast Cancer Res Treat (2004) 1.78
Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med (2003) 1.74
Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J Nucl Med (2006) 1.58
123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1/Cip-1). Eur J Nucl Med Mol Imaging (2006) 1.48
Pharmacological blockade of the cold receptor TRPM8 attenuates autonomic and behavioral cold defenses and decreases deep body temperature. J Neurosci (2012) 1.46
Influence of formulation variables on the biodistribution of multifunctional block copolymer micelles. J Control Release (2011) 1.43
Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences. J Nucl Med (2008) 1.41
The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharm (2010) 1.35
Endothelial apoptosis initiates acute blood-brain barrier disruption after ionizing radiation. Cancer Res (2003) 1.33
Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis. Breast J (2006) 1.29
Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging (2008) 1.26
(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med (2007) 1.25
Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther (2004) 1.21
A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer. Cancer Res (2005) 1.21
Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J Pharmacol Exp Ther (2008) 1.21
Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients. Breast Cancer Res Treat (2010) 1.18
Are health-care relationships important for mammography adherence in Latinas? J Gen Intern Med (2008) 1.13
Early radiation-induced endothelial cell loss and blood-spinal cord barrier breakdown in the rat spinal cord. Radiat Res (2004) 1.12
Surgical management of early stage invasive breast cancer: a practice guideline. Can J Surg (2005) 1.12
Optimized digital counting colonies of clonogenic assays using ImageJ software and customized macros: comparison with manual counting. Int J Radiat Biol (2011) 1.09
Computational analysis of the number, area and density of gamma-H2AX foci in breast cancer cells exposed to (111)In-DTPA-hEGF or gamma-rays using Image-J software. Int J Radiat Biol (2009) 1.08
Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer. Mod Pathol (2007) 1.08
Outcomes of surveillance mammography after treatment of primary breast cancer: a population-based case series. Breast Cancer Res Treat (2008) 1.08
Detection of lymphatic invasion in primary melanoma with monoclonal antibody D2-40: a new selective immunohistochemical marker of lymphatic endothelium. Arch Dermatol (2005) 1.06
Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event. Breast J (2007) 1.06
Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Res Treat (2006) 1.04
A human transferrin-vascular endothelial growth factor (hnTf-VEGF) fusion protein containing an integrated binding site for (111)In for imaging tumor angiogenesis. J Nucl Med (2005) 1.01
Molecularly targeted gold nanoparticles enhance the radiation response of breast cancer cells and tumor xenografts to X-radiation. Breast Cancer Res Treat (2012) 1.01
IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways. Breast Cancer Res Treat (2011) 1.00
Cultural views, language ability, and mammography use in Chinese American women. Health Educ Behav (2009) 0.99
Changes in psychosocial functioning 1 year after mastectomy alone, delayed breast reconstruction, or immediate breast reconstruction. Ann Surg Oncol (2011) 0.98
Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Res Treat (2005) 0.97
In vivo distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels. Pharm Res (2010) 0.96
Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Nucl Med Commun (2005) 0.96
Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate. J Nucl Med (2008) 0.95
Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med (2009) 0.94
Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts. J Nucl Med (2010) 0.92
Synthesis and preliminary biological evaluations of [18F]-1-deoxy-1-fluoro-scyllo-inositol. Chem Commun (Camb) (2009) 0.91
Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor. J Nucl Med (2007) 0.91
Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm (2008) 0.90
Apoptotic epidermal growth factor (EGF)-conjugated block copolymer micelles as a nanotechnology platform for targeted combination therapy. Mol Pharm (2007) 0.90
Breast metastasis by medullary thyroid carcinoma detected by FDG positron emission tomography. Ann Diagn Pathol (2007) 0.89
Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo. Mol Pharm (2012) 0.89
Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF. J Nucl Med (2008) 0.88
Etiologic factors associated with p53 immunostaining in cutaneousmalignant melanoma. Int J Cancer (2005) 0.88
A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT. EJNMMI Res (2011) 0.88
Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population. J Nucl Med (2011) 0.87
Noninvasive monitoring of the fate of 111In-labeled block copolymer micelles by high resolution and high sensitivity microSPECT/CT imaging. Mol Pharm (2009) 0.87
In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. Int J Cancer (2006) 0.87
Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF. Nucl Med Biol (2007) 0.86
Breast cancer metastasis in a human bone NOD/SCID mouse model. Cancer Biol Ther (2007) 0.86
Design and characterization of HER-2-targeted gold nanoparticles for enhanced X-radiation treatment of locally advanced breast cancer. Mol Pharm (2010) 0.86
Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging. J Nucl Med (2005) 0.85
Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice. Nucl Med Biol (2011) 0.85
Construction and evaluation of the tumor imaging properties of 123I-labeled recombinant and enzymatically generated Fab fragments of the TAG-72 monoclonal antibody CC49. Bioconjug Chem (2007) 0.84
Cellular penetration and nuclear importation properties of 111In-labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells. Nucl Med Biol (2007) 0.84
18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice. J Nucl Med (2009) 0.84
Block copolymer micelles target Auger electron radiotherapy to the nucleus of HER2-positive breast cancer cells. Biomacromolecules (2012) 0.83
MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates. Breast Cancer Res Treat (2013) 0.82
Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties. Cancer Chemother Pharmacol (2006) 0.82
Biological Markers Predictive of Invasive Recurrence in DCIS. Clin Med Oncol (2008) 0.82
A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer. Nucl Med Biol (2010) 0.81
Multifunctional block copolymer micelles for the delivery of 111In to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy. Mol Pharm (2010) 0.81
Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab. J Nucl Med (2010) 0.81
A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications. J Nucl Med (2004) 0.81
Estrone-3-sulphate, a potential novel ligand for targeting breast cancers. PLoS One (2013) 0.80
Functional comparison of single- and double-stranded mdr1 antisense oligodeoxynucleotides in human ovarian cancer cell lines. J Pharm Pharm Sci (2005) 0.79
Effect of pendant group structure on the hydrolytic stability of polyaspartamide polymers under physiological conditions. Biomacromolecules (2012) 0.79
The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Nucl Med Biol (2008) 0.79
HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1. Bioconjug Chem (2006) 0.78
Development of an epidermal growth factor derivative with EGFR blocking activity. PLoS One (2013) 0.78
Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates. J Nucl Med (2012) 0.78
Investigation of the effects of cell model and subcellular location of gold nanoparticles on nuclear dose enhancement factors using Monte Carlo simulation. Med Phys (2013) 0.78
111In- or 99mTc-labeled recombinant VEGF bioconjugates: in vitro evaluation of their cytotoxicity on porcine aortic endothelial cells overexpressing Flt-1 receptors. Nucl Med Biol (2009) 0.78